Edition:
United States

Indivior PLC (INDV.L)

INDV.L on London Stock Exchange

208.20GBp
19 Nov 2018
Change (% chg)

5.90 (+2.92%)
Prev Close
202.30
Open
201.20
Day's High
215.60
Day's Low
199.90
Volume
696,069
Avg. Vol
3,164,168
52-wk High
504.60
52-wk Low
169.30

Chart for

About

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue... (more)

Overall

Beta: 1.50
Market Cap(Mil.): £1,587.25
Shares Outstanding(Mil.): 728.44
Dividend: --
Yield (%): --

Financials

  INDV.L Industry Sector
P/E (TTM): 21.42 28.12 29.34
EPS (TTM): 0.10 -- --
ROI: 22.62 14.10 13.58
ROE: -- 15.67 15.11

Indivior slashes revenue outlook for Sublocade, shares tank

Indivior Plc cut its expectations for revenue from injectable opioid addiction drug Sublocade on Wednesday and said it had "substantially underestimated" the delay in getting the drug to patients although it remained confident of its potential.

Sep 26 2018

UPDATE 2-Indivior slashes revenue outlook for Sublocade, shares tank

* Shares plunge over 16 pct (Adds details, background, CEO comment)

Sep 26 2018

Indivior sharply lowers revenue outlook for opioid addiction drug Sublocade

Sept 26 Indivior Plc revised its full-year earnings guidance as it sharply lowered its revenue expectation for opioid addiction drug Sublocade on Wednesday.

Sep 26 2018

Teva to hold Indivior generic drug launch pending U.S. ruling

Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Sep 12 2018

UPDATE 1-Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Sep 12 2018

Teva to hold Indivior generic drug launch pending U.S. ruling

Sept 12 Teva Pharmaceuticals has agreed to hold off launching its knock-off version of Indivior Plc's blockbuster opioid addiction drug until the resolution of a U.S. Court case on another generic rival, Indivior said on Wednesday.

Sep 12 2018

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Aug 08 2018

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

Aug 8 The U.S. Justice Department has joined several whistleblower lawsuits against Indivior Plc and Reckitt Benckiser Group PLC, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Aug 08 2018

Indivior: U.S. court rules against generic rival's appeal

Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Jul 31 2018

UPDATE 1-Indivior: U.S. court rules against generic rival's appeal

July 31 Indivior Plc notched a legal victory on Tuesday after a U.S. court reaffirmed that a generic rival could not re-launch cheaper versions of the British drugmaker's best-selling opioid addiction treatment in the United States.

Jul 31 2018

Earnings vs. Estimates